Overexpression of thymosin β4 increases pseudopodia formation in LNCaP prostate cancer cells

Biological and Pharmaceutical Bulletin

Volumn 32, Issue 6, 2009, Pages 1101-1104

  Ito, Mai ^a   Iguchi, Kazuhiro ^a   Usui, Shigeyuki ^a   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

LNCaP; Migration; Pseudopodia; Thymosin 4

Indexed keywords

ACTIN; ANDROGEN; CLOSTRIDIUM DIFFICILE TOXIN B; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN CDC42; RAC1 PROTEIN; RHO KINASE; THYMOSIN BETA4; WORTMANNIN; 1,3 BUTADIENE DERIVATIVE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANDROSTANE DERIVATIVE; BACTERIAL PROTEIN; BACTERIAL TOXIN; NITRILE; PHOSPHATIDYLINOSITOL 3 KINASE; RAC1 PROTEIN, HUMAN; RAPAMYCIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THYMOSIN; THYMOSIN BETA(4); TOXB PROTEIN, CLOSTRIDIUM DIFFICILE;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CELL LINE; CELL MIGRATION; HUMAN; HUMAN CELL; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PSEUDOPODIUM; UPREGULATION; BIOSYNTHESIS; CELL MOTION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; GENETIC TRANSFECTION; MALE; METABOLISM; PATHOLOGY; PHASE CONTRAST MICROSCOPY; PROSTATE TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANDROSTADIENES; BACTERIAL PROTEINS; BACTERIAL TOXINS; BUTADIENES; CDC42 GTP-BINDING PROTEIN; CELL LINE, TUMOR; CELL MOVEMENT; HUMANS; MALE; MICROSCOPY, PHASE-CONTRAST; NITRILES; PROSTATIC NEOPLASMS; PSEUDOPODIA; RAC1 GTP-BINDING PROTEIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RHOA GTP-BINDING PROTEIN; SIROLIMUS; THYMOSIN; TRANSFECTION;

EID: 66549099376     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.32.1101     Document Type: Article

References (21)

1. Huggins C., Hodges C. V., Cancer Res., 1, 293-297 (1941).
2. Isaacs J. T., BJU Int., 96, 35-40 (2005).
3. Emmett J. L., Greene L. F., Papantoniou A., J. Urol., 83, 471-484 (1960).
4. Holzbeierlein J., Lal P., LaTulippe E., Smith A., Satagopan J., Zhang L., Ryan C., Smith S., Scher H., Scardino P., Reuter V., Gerald W. L., Am. J. Pathol., 164, 217-227 (2004).
5. Kleeberger W., Bova G. S., Nielsen M. E., Herawi M., Chuang A. Y., Epstein J. I., Berman D. M., Cancer Res., 67, 9199-9206 (2007).
6. Iguchi K., Ito M., Usui S., Mizokami A., Namiki M., Hirano K., J. Androl., 29, 207-212 (2008).
7. Safer D., Elzinga M., Nachmias V. T., J. Biol. Chem., 266, 4029-4032 (1991).
8. Sosne G., Chan C. C., Thai K., Kennedy M., Szliter E. A., Hazlett L. D., Kleinman H. K., Exp. Eye Res., 72, 605-608 (2001).
9. Kobayashi T., Okada F., Fujii N., Tomita N., Ito S., Tazawa H., Aoyama T., Choi S. K., Shibata T., Fujita H., Hosokawa M., Am. J. Pathol., 160, 869-882 (2002).
10. Cha H. J., Jeong M. J., Kleinman H. K., J. Natl. Cancer Inst., 95, 1674-1680 (2003).
11. Yamamoto T., Gotoh M., Kitajima M., Hirohashi S., Biochem. Biophys. Res. Commun., 193, 706-710 (1993).
12. Clark E. A., Golub T. R., Lander E. S., Hynes R. O., Nature (London), 406, 532-535 (2000).
13. Vigneswaran N., Wu J., Sacks P., Gilcrease M., Zacharias W., J. Oral Pathol. Med., 34, 77-86 (2005).
14. Bock-Marquette I., Saxena A., White M. D., Dimaio J. M., Srivastava D., Nature (London), 432, 466-472 (2004).
15. Ishii K., Usui S., Sugimura Y., Yoshida S., Hioki T., Tatematsu M., Yamamoto H., Hirano K., Int. J. Cancer, 92, 49-54 (2001).
16. Al-Nedawi K. N., Czyz M., Bednarek R., Szemraj J., Swiatkowska M., Cierniewska-Cieslak A., Wyczolkowska J., Cierniewski C. S., Blood, 103, 1319-1324 (2004).
17. Frohm M, Gunne H, Bergman A. C., Agerberth B., Bergman T., Boman A., Lidén S., Jörnvall H., Boman H. G., Eur. J. Biochem., 237, 86-92 (1996).
18. Huang W. Q., Wang Q. R., Exp. Hematol., 29, 12-18 (2001).
19. Wang W. S., Chen P. M., Hsiao H. L., Ju S. Y., Su Y., Oncogene, 22, 3297-3306 (2003).
20. Wang W. S., Chen P. M., Hsiao H. L., Wang H. S., Liang W. Y., Su Y., Oncogene, 23, 6666-6671 (2004).
21. Huang H. C., Hu C. H., Tang M. C., Wang W. S., Chen P. M., Su Y., Oncogene, 26, 2781-2790 (2007).